

M a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), [and other agents containing soluble TNF receptors,] CDP571 (a humanized monoclonal anti-TNF-alpha antibody), [other monoclonal anti-TNF-alpha antibodies, TNF - alpha converting enzyme inhibitors] and D2E7 (a human anti-TNF mAb) for reducing the inflammation of muscle of said human, or for modulating the immune response affecting the muscle of said human.

Please add new Claim 100 as follows:

A 100. A method for inhibiting the action of TNF in accordance with Claim 50, wherein the step of administering said dosage level is for treating muscular inflammation resulting from sports injuries or muscle injuries, and for preventing muscular inflammation resulting from muscular activity. B